SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

JNJ-42226314

Item No. 41115

CAS Registry No.:	1252765-13-1
Formal Name:	[4-[1-[[1-(4-fluorophenyl)-1H-indol-5-yl]carbonyl]-3-azetidinyl]-1-piperazinyl]-2-thiazolyl-methanone
MF:	$C_{26}H_{24}FN_5O_2S$
FW:	489.6
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

JNJ-42226314 is supplied as a solid. A stock solution may be made by dissolving the JNJ-42226314 in the solvent of choice, which should be purged with an inert gas. JNJ-42226314 is sparingly soluble (1-10 mg/ml) in the organic solvent DMSO.

Description

JNJ-42226314 is an inhibitor of monoacylglycerol lipase (MAGL; IC_{50} = 10 nM).[1] It is selective for MAGL over a panel of 15 serine proteases at 10 µM. JNJ-42226314 (30 mg/kg) increases the latency to paw withdrawal in the hot plate test and the brain levels of 2-arachidonoyl glycerol (2-AG; Item No. 62160) in rats. It increases the latency to fall asleep and the development of non-rapid eye movement (NREM) and REM sleep, as well as increases the cortical levels of norepinephrine, in rats when administered at a dose of 30 mg/kg.[2] Radiolabeled forms of JNJ-42226314 have been used for autoradiography and PET tracers for MAGL in the brains of rats and rhesus monkeys.[3]

References

1. Zhu, B., Connolly, P.J., Zhang, Y.M., *et al.* The discovery of azetidine-piperazine di-amides as potent, selective and reversible monoacylglycerol lipase (MAGL) inhibitors. *Bioorg. Med. Chem. Lett.* **30(14)**, 127243 (2020).
2. Wyatt, R.M., Fraser, I., Welty, N., *et al.* Pharmacologic characterization of JNJ-42226314, [1-(4-fluorophenyl)indol-5-yl]-[3-[4-(thiazole-2-carbonyl)piperazin-1-yl]azetidin-1-yl]methanone, a reversible, selective, and potent monoacylglycerol lipase inhibitor. *J. Pharmacol. Exp. Ther.* **372(3)**, 339-353 (2020).
3. Rong, J., Mori, W., Xia, X., *et al.* Novel reversible-binding PET ligands for imaging monoacylglycerol lipase based on the piperazinyl azetidine scaffold. *J. Med. Chem.* **64(19)**, 14283-14298 (2021).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM